{"id":23755,"date":"2024-04-15T17:05:56","date_gmt":"2024-04-15T15:05:56","guid":{"rendered":"https:\/\/ggba.swiss\/oculis-announces-completion-of-oversubscribed-usd-59-million-registered-direct-offering\/"},"modified":"2024-04-15T17:07:51","modified_gmt":"2024-04-15T15:07:51","slug":"oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/","title":{"rendered":"Oculis r\u00e9alise une offre directe enregistr\u00e9e sursouscrite de USD 59 millions"},"content":{"rendered":"\n<p><a href=\"https:\/\/oculis.com\/\">Oculis Holding AG<\/a>, une soci\u00e9t\u00e9 biopharmaceutique mondiale de premier plan dont l&rsquo;objectif est de pr\u00e9server la vue et d&rsquo;am\u00e9liorer les soins oculaires, a annonc\u00e9 la r\u00e9ussite de son tour de table et sa cotation sur le NASDAQ Iceland Main Market. La soci\u00e9t\u00e9 vaudoise, connue pour ses traitements ophtalmologiques innovants, a lev\u00e9 environ USD 59 millions par l&rsquo;\u00e9mission de 5&rsquo;000&rsquo;000 d&rsquo;actions ordinaires \u00e0 un prix d&rsquo;achat de USD 11,75 par action.<\/p>\n\n\n\n<p>La r\u00e9alisation de cette offre directe enregistr\u00e9e marque un moment charni\u00e8re pour Oculis, qui est doublement cot\u00e9e aux \u00c9tats-Unis et maintenant en Islande, o\u00f9 sa technologie propri\u00e9taire OPTIREACH\u00ae a \u00e9t\u00e9 d\u00e9velopp\u00e9e. \u00ab&nbsp;Nous sommes heureux de devenir l&rsquo;une des rares soci\u00e9t\u00e9s de biotechnologie cot\u00e9es \u00e0 la fois aux \u00c9tats-Unis et en Islande&nbsp;\u00bb, a d\u00e9clar\u00e9 Riad Sherif, M.D., CEO d&rsquo;Oculis. Il a exprim\u00e9 sa gratitude envers le nouveau syndicat d&rsquo;investisseurs pour leur soutien et a fait part de son enthousiasme quant aux prochains r\u00e9sultats de l&rsquo;essai RELIEF de phase 2b d&rsquo;OCS-02 sur la s\u00e9cheresse oculaire, attendus plus tard au cours de ce trimestre.<\/p>\n\n\n\n<p>Cette \u00e9tape financi\u00e8re fait suite \u00e0 d&rsquo;importantes r\u00e9alisations d&rsquo;Oculis, notamment <a href=\"https:\/\/ggba.swiss\/fr\/oculis-fait-son-entree-au-nasdaq-avec-un-pipeline-prometteur-en-ophtalmologie\/\">sa cotation sur le Nasdaq Global Market en 2023<\/a>, sous le symbole \u00ab&nbsp;OCS&nbsp;\u00bb. La soci\u00e9t\u00e9 s&rsquo;est impos\u00e9e dans le paysage biopharmaceutique international en proposant des produits candidats innovants pour des pathologies ophtalmiques critiques.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Des th\u00e9rapies transformatrices pour les maladies oculaires<\/h4>\n\n\n\n<p>Les fonds provenant de l&rsquo;offre sont destin\u00e9s \u00e0 faire progresser le pipeline de d\u00e9veloppement clinique d&rsquo;Oculis, ainsi qu&rsquo;\u00e0 des besoins g\u00e9n\u00e9raux de l&rsquo;entreprise. La soci\u00e9t\u00e9 estime que ces fonds soutiendront ses op\u00e9rations et ses besoins en d\u00e9penses d&rsquo;investissement jusqu&rsquo;au second semestre 2026.<\/p>\n\n\n\n<p>Le prospectus d&rsquo;Oculis pour l&rsquo;admission de ses actions sur le NASDAQ Iceland Main Market a \u00e9t\u00e9 approuv\u00e9 par la Central Bank of Iceland, soulignant la solide position r\u00e9glementaire et financi\u00e8re de l&rsquo;entreprise.<\/p>\n\n\n\n<p>Arctica Finance ehf. a assur\u00e9 la supervision du processus de cotation, tandis que BBA\/\/Fjeldco, Cooley LLP et Vischer AG ont agi en qualit\u00e9 de conseillers juridiques. Cette man\u0153uvre financi\u00e8re strat\u00e9gique souligne non seulement la solide position d&rsquo;Oculis sur le march\u00e9, mais renforce \u00e9galement son engagement \u00e0 d\u00e9velopper des th\u00e9rapies transformatrices pour les maladies affectant les yeux afin d&rsquo;apporter une valeur significative aux patients, aux m\u00e9decins et aux investisseurs du monde entier.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu&rsquo;en 2026 suite \u00e0 une cotation r\u00e9ussie sur le NASDAQ Iceland Main Market.<\/p>\n","protected":false},"author":6,"featured_media":23752,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1141],"class_list":["post-23755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oculis r\u00e9alise une offre directe sursouscrite de USD 59 millions<\/title>\n<meta name=\"description\" content=\"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu&#039;en 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oculis r\u00e9alise une offre directe sursouscrite de USD 59 millions\" \/>\n<meta property=\"og:description\" content=\"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu&#039;en 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-15T15:05:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-15T15:07:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Oculis r\u00e9alise une offre directe enregistr\u00e9e sursouscrite de USD 59 millions\",\"datePublished\":\"2024-04-15T15:05:56+00:00\",\"dateModified\":\"2024-04-15T15:07:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\"},\"wordCount\":435,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\",\"name\":\"Oculis r\u00e9alise une offre directe sursouscrite de USD 59 millions\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg\",\"datePublished\":\"2024-04-15T15:05:56+00:00\",\"dateModified\":\"2024-04-15T15:07:51+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu'en 2026.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu'en 2026 suite \u00e0 une cotation r\u00e9ussie sur le NASDAQ Iceland Main Market.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oculis r\u00e9alise une offre directe enregistr\u00e9e sursouscrite de USD 59 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oculis r\u00e9alise une offre directe sursouscrite de USD 59 millions","description":"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu'en 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"Oculis r\u00e9alise une offre directe sursouscrite de USD 59 millions","og_description":"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu'en 2026.","og_url":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-04-15T15:05:56+00:00","article_modified_time":"2024-04-15T15:07:51+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Oculis r\u00e9alise une offre directe enregistr\u00e9e sursouscrite de USD 59 millions","datePublished":"2024-04-15T15:05:56+00:00","dateModified":"2024-04-15T15:07:51+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/"},"wordCount":435,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg","keywords":["Biotech","Financing","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/","url":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/","name":"Oculis r\u00e9alise une offre directe sursouscrite de USD 59 millions","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg","datePublished":"2024-04-15T15:05:56+00:00","dateModified":"2024-04-15T15:07:51+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu'en 2026.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Oculis-Eye-59-million-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a obtenu USD 59 millions pour prolonger ses activit\u00e9s jusqu'en 2026 suite \u00e0 une cotation r\u00e9ussie sur le NASDAQ Iceland Main Market."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Oculis r\u00e9alise une offre directe enregistr\u00e9e sursouscrite de USD 59 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=23755"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23755\/revisions"}],"predecessor-version":[{"id":23757,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23755\/revisions\/23757"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/23752"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=23755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=23755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=23755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}